tudies suggest that HCG, like Gonadorelin, may act as an agonist at GnRH receptors to stimulate the production of gonadotropins. HCG was originally extracted from animal placentas but is now generated commercially using recombinant genetic processes. Gonadorelin is a biochemically-manufactured synthetic peptide. Research suggests that although they may operate on the same receptor and provide comparable results, these compounds are not interchangeable. Gonadorelin has been suggested to have a wider range of positive properties than other substances and is also believed to be more convenient to keep. We’ll compare and contrast these two substances and examine their research applications here.
Gonadorelin vs. HCG
Chorionic gonadotropin (HCG) is a large peptide with a molecular weight of 36,700 g/mol and a sequence of 237 amino acids. Since HCG is produced by trophoblast cells in the placenta, it is often quantified in blood or urine to diagnose pregnancy. Findings imply that it may also be a potential marker for cancer cell detection. HCG has been suggested to stimulate weight reduction, most likely through altering adipose tissue. This assertion, however, has proven challenging to validate because of the wide variation in speculated outcomes.
The chorionic gonadotropin (HCG) molecule consists of two separate proteins that are “stuck” together. Investigations purport that HCG’s alpha subunit may act similarly to follicle-stimulating and luteinizing hormones. HCG’s beta subunit seems to be the active component, similar to luteinizing hormone.
Gonadorelin consists of just 10 amino acids and has a very low molecular weight of 1,182 g/mol. Scientists hypothesize that to induce the production of luteinizing hormone, follicle-stimulating hormone (FSH), and (to a lesser degree) thyroid-stimulating hormone, this synthetic GnRH analog may act on the pituitary gland. Infertility, menstrual cycle abnormalities, and hypogonadism are among the contexts for which this peptide has been studied.
Gonadorelin vs. HCG: Testosterone Levels
Researchers speculate that both Gonadorelin and HCG may boost testosterone levels. It is believed that they may do this by triggering the production of luteinizing hormone (LH), which may encourage hormone production in the testes and the ovaries. The result is speculated to be a dramatic rise in testosterone levels in males. Although it may potentially induce a similar rise in testosterone levels in females, the ensuing rise in estrogen levels is considered far more noticeable. It has been purported that in addition to promoting sperm and egg production in the testes and ovaries, these chemicals may also increase the release of FSH.
Despite popular belief, it has been hypothesized that FSH does not stimulate more testosterone production. Instead, it may raise the amount of androgen-binding proteins in the testes, which boosts local androgen concentrations by removing the hormone from general supply. Testosterone levels rise locally in the testicles, leading to an uptick in sperm production. Both male and female research models have been reported to yield positive results from higher FSH levels, as more sperm and eggs are produced. However, it is believed it may not affect the production of sexual hormones.
Researchers speculate that maintaining optimal testosterone levels may support neurological protection. However, higher LH levels have also previously been linked to neurocognitive dysfunction. Overall, the study suggested improved cognitive performance when both LH and testosterone levels were increased, suggesting that the effect of testosterone remains even if LH levels are also raised. However, research is ongoing into the possible organized use of Gonadorelin to boost long-term cognitive health in research using animal research models.
Recent studies have suggested that GnRH agonists like Gonadorelin may improve communication between the left and right sides of the brain. This could have a cumulative impact on mental functions, especially in visual processing and memory. This suggested that concerns raised about previous studies were warranted and that GnRH agonists may likely enhance cognitive function. There will, of course, be more studies conducted on the subject because of this.
Gonadorelin vs. HCG: Research Applications
It has been hypothesized that HCG may have limited research applications. It is believed that pregnancy diagnosis, monitoring, and management of some reproductive-system cancers may be its primary testing applications. Findings imply that chorionic gonadotropin (HCG) may have supported the ovulation and conception processes exhibited in female research models. In polycystic ovary syndrome-related hypogonadism cases, it has been speculated to support function and potentially mitigate harmful symptoms. HCG has been speculated to increase fertility in male research models.
Gonadorelin (GnRH) may be found for sale at Core Peptides, along with a wide range of other similar research compounds for scientific studies.
[i] H. Yamasaki, T. Douchi, S. Yamamoto, T. Oki, R. Kuwahata, and Y. Nagata, “Body fat distribution and body composition during GnRH agonist therapy,” Obstet. Gynecol., vol. 97, no. 3, pp. 338–342, Mar. 2001, doi: 10.1016/s0029-7844(00)01181-9.
[ii] A. Cáceres, J. E. Vargas, and J. R. González, “APOE and MS4A6A interact with GnRH signaling in Alzheimer’s disease: Enrichment of epistatic effects,” Alzheimers Dement. J. Alzheimers Assoc., vol. 13, no. 4, pp. 493–497, Apr. 2017, doi: 10.1016/j.jalz.2016.05.009.
[iii] T. Chen et al., “Influence of Gonadotropin Hormone Releasing Hormone Agonists on Interhemispheric Functional Connectivity in Girls With Idiopathic Central Precocious Puberty,” Front. Neurol., vol. 11, p. 17, Jan. 2020, doi: 10.3389/fneur.2020.00017.
[iv] “Sex steroids and breast cancer prevention. – Abstract – Europe PMC.” https://europepmc.org/article/med/7999456